您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Raceanisodamine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Raceanisodamine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Raceanisodamine图片
CAS NO:17659-49-3
包装与价格:
包装价格(元)
250mg电议
500mg电议
1g电议

产品介绍

化学性质

StorageStore at -20°C
M.Wt305.37
Cas No.17659-49-3
FormulaC17H23NO4
Synonyms6-hydroxy Hyoscyamine
Solubility≥13.32 mg/mL in EtOH; ≥13.65 mg/mL in H2O; ≥51.3 mg/mL in DMSO
Chemical Name6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate
Canonical SMILESOCC(C(OC1CC(N2C)CC(O)C2C1)=O)C3=CC=CC=C3
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

Raceanisodamine is a weak antagonist of α1-adrenergic receptors [1].

The adrenergic receptors play an important role in modulating sympathetic nervous system activity as well as a site of action for many therapeutic agents. The α1-adrenergic receptors contain three types, termed as α1A-, α1B-, and α1D. The α1-adrenergic receptor plays an essential role in smooth muscle, growth, neurological, and cardiovascular function [2]. With the binding of the endogenous ligands, epinephrine and norepinephrine, the adrenergic receptors are the prime mediators of smooth muscle contraction and hypertrophic growth [2].

Raceanisodamine was a natural tropane alkaloid predominantly found in the roots of A. tanguticus. Raceanisodamine weakly antagonized the activity of α1-adrenoceptors and blocked WB-4101 and clonidine binding in brain membrane preparations with pKi values of 2.63 and 1.61, respectively [1]. Raceanisodamine showed antioxidant effects and protected against free radical-induced cellular damage [3].

References:
[1] Varma D R, Yue T L. Adrenoceptor blocking properties of atropine‐like agents anisodamine and anisodine on brain and cardiovascular tissues of rats[J]. British journal of pharmacology, 1986, 87(3): 587-594.
[2] Piascik M T, Perez D M. α1-Adrenergic receptors: new insights and directions[J]. Journal of Pharmacology and Experimental Therapeutics, 2001, 298(2): 403-410.
[3] Poupko J M, Baskin S I, Moore E. The pharmacological properties of anisodamine[J]. Journal of Applied Toxicology, 2007, 27(2): 116-121.